Breast Cancer

Study challenges previous findings that suggest night shift work increases the risk of breast cancer.

Inhibiting Ran-GTP was associated with reversing and preventing treatment-resistant cancers.

Premenopausal, overweight women have a decreased risk of breast cancer, while postmenopausal women have an increased risk.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

LEE011 plus letrozole may prove to be effective first-line breast cancer therapy.

LEE011 plus letrozole demonstrates significant progression free survival in patients with breast cancer.

Device shows promise preventing cancer cells from migrating to other organs in the body.

Using precision medicine, researchers were able to slow down the amount of time it takes for a tumor to grow back in patients with advanced cancer.

Tumor cells grown in mice first could potentially change the cancer research landscape.

Environmental exposure to common chemicals found to inhibit tamoxifen efficacy in breast cancer patients.

Stiffness and hypoxia environments triggers the spread of breast cancer.

Pevonedistat, currently being tested in clinical trials, shows promise in killing melanomas and other cancer types.

New mouse study suggests that exposure to endocrine disrupting chemicals may cause resistance to tamoxifen therapy in some breast cancers.

High body mass index linked to 10 types of cancer, including cancers of the breast, bowel, esophageal, and womb.

Immunotherapy able to kill triple-negative breast cancer cells via two-pronged strategy.

Higher levels of transport genes are an indicator of patients likely to be resistant to therapy with tamoxifen.

Experimental drug shows promise killing triple negative breast cancer cells.

Little clinical data exists to aid shared decision making for mammography frequency.

Nebivolol shows promise blocking anthracycline-induced cardiotoxicity in breast cancer patients.

Patients with negative expectations about breast cancer treatment had nearly twice the amount of side effects.

Genetic mechanisms could potentially promote cancer growth and spread.

Expanded use of bundled payments in cancer for services such as mammography.

Some breast cancer tumors are not sensitive to Herceptin.

Duration and degree of being overweight impacts cancer risk in postmenopausal women.